Madopar Cr

Levodopa, the active ingredient in Madopar CR, is a dopamine precursor presented as a controlled‑release tablet for oral use. It treats Parkinson's disease by replenishing central dopamine in patients with this neurodegenerative disorder, helping to improve motor function and reduce rigidity and tremor. The formulation ensures steady plasma concentrations over several hours, which can lessen the frequency of dosing compared with immediate‑release preparations.

GNH USA supplies Madopar CR as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and logistics for global healthcare providers and after‑sales service.

Madopar CR is used in the management of Parkinsonian disorders, targeting the dopaminergic pathway to improve motor symptoms.

- Parkinson's disease: improves motor control, reducing rigidity and tremor. - Parkinsonian syndrome: alleviates bradykinesia and gait disturbances. - Motor fluctuations in Parkinson's disease: provides more stable symptom control throughout the day.

Levodopa/Benserazide may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea: upset stomach often occurring at treatment initiation. - Dizziness: light‑headedness, especially when standing quickly. - Orthostatic hypotension: drop in blood pressure upon standing. - Headache: mild to moderate intensity. - Insomnia: difficulty falling or staying asleep. - Dyskinesia: involuntary movements, especially with higher doses.

Serious or Rare Side Effects: - Hallucinations or psychosis: visual or auditory disturbances requiring medical review. - Severe hypotension: marked blood pressure drop that may cause fainting. - Cardiac arrhythmias: irregular heart rhythms observed in susceptible patients. - Anaphylactic reaction: rare but potentially life‑threatening allergy.

When prescribing Madopar CR, several safety considerations should be observed.

- Renal impairment: adjust dose or monitor closely. - Hepatic impairment: use with caution and monitor liver function. - Cardiovascular disease: monitor blood pressure and heart rate. - History of melanoma or other cancers: evaluate risk versus benefit. - Concomitant MAO‑B inhibitors: avoid use within 14 days of stopping. - Pregnancy and breastfeeding: safety not established; prescribe only if essential. - Store at ambient temperature: keep in original container, protect from moisture and light.

Madopar CR can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotic agents (e.g., haloperidol): may diminish therapeutic effect. - High‑protein meals: can reduce levodopa absorption and efficacy.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (selegiline, rasagiline): may increase levodopa levels. - Antihypertensive drugs: additive hypotensive effect. - SSRIs or SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.